Dr Reddys Laboratories (RDY) EBITDA Margin Growth (3y) (2012 - 2023)
Dr Reddys Laboratories (RDY) EBITDA Margin Growth (3y) (2012 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | -4,186.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 898.00 |
| Mar 31, 2023 | 1,376.00 |
| Sep 30, 2022 | 3,763.00 |
| Jun 30, 2021 | 762.00 |
| Mar 31, 2021 | 56.00 |
| Sep 30, 2020 | -3,544.00 |
| Sep 30, 2019 | -3,253.00 |
| Mar 31, 2019 | 12.00 |
| Dec 31, 2018 | 1,325.00 |
| Sep 30, 2018 | 1,490.00 |
| Jun 30, 2018 | -979.00 |
| Dec 31, 2017 | -822.00 |
| Sep 30, 2017 | 113.00 |
| Dec 31, 2016 | -791.00 |
| Sep 30, 2016 | 1,918.00 |
| Mar 31, 2016 | 2,073.00 |
| Dec 31, 2015 | 0.00 |
| Sep 30, 2015 | -2,644.00 |
| Jun 30, 2015 | 252.00 |
| Dec 31, 2014 | 9.00 |